NEW YORK – Magnolia Medical said on Wednesday it has signed a three-year purchasing agreement with Intalere covering Magnolia's Steripath Gen2 Initial Specimen Diversion Device product portfolio.
Other terms of the deal were not disclosed.
As part of the deal, Intalere member hospitals will receive "increased value" and cost savings, as well as access to Magnolia's alliance member pricing and clinical performance guarantee for Steripath. The Steripath Gen2 ISDD product portfolio includes direct-to-media and integrated syringe configurations.
According to the Seattle-based company, they are the only US Food and Drug Administration 510(k)-cleared devices indicated to reduce blood culture contamination. The Steripath Gen2 platform integrates negative pressure to divert and sequester the initial 1.5 mL to 2.0 mL of collected blood – the portion most likely to contain contaminants – for culture.
"Magnolia and Intalere share common goals of preventing patient harm and driving antibiotic stewardship while significantly reducing healthcare costs which are all further enabled with the unique program we are offering under this agreement," Greg Bullington, CEO and cofounder of Magnolia Medical said in a statement.
Based in St. Louis, Intalere advises healthcare organizations on how to improve their financial, operational, and clinical performance.